LUND, Sweden, Nov. 23, 2015 (GLOBE NEWSWIRE) -- In accordance with a decision made by the Annual General Meeting held on June 11, 2015, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2015, and the Chairman of the Board.
For the 2016 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders and, accordingly, are members of the Election Committee:
Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Lennart Johansson, Investor
Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals for the Board of Directors that are to be presented to and decided upon at the Annual General Meeting on May 26, 2016.
Lund, November 23, 2015
Active Biotech AB (publ)
President and CEO
Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the ISI, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was provided to the media for publication at 8:30 am CET on November 23, 2015.
Active Biotech's election committee appointed http://hugin.info/1002/R/1968440/719334.pdf
Source: Active Biotech